Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma

Treatment of metastatic renal cell carcinoma (mRCC) with agents that block signaling through vascular endothelial growth factor receptor 2 (VEGFR2) induces disease regression or stabilization in some patients; however, these responses tend to be short-lived. Therefore, development of combination the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaoen, Solban, Nicolas, Khanna, Prateek, Callea, Marcella, Song, Jiaxi, Alsop, David C., Pearsall, R. Scott, Atkins, Michael B., Mier, James W., Signoretti, Sabina, Alimzhanov, Marat, Kumar, Ravi, Bhasin, Manoj K., Bhatt, Rupal S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173101/
https://www.ncbi.nlm.nih.gov/pubmed/27248821
http://dx.doi.org/10.18632/oncotarget.9621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5173101/
https://www.ncbi.nlm.nih.gov/pubmed/27248821
http://dx.doi.org/10.18632/oncotarget.9621

Ejemplares similares